GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide
19 10월 2023 - 10:00PM
Business Wire
Integration allows people living with diabetes
– with or without insurance – to access Sanofi’s most-prescribed
insulin at a fixed rate anywhere GoodRx is accepted
GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings
and information, today announced it is working with Sanofi (NASDAQ:
SNY), a global leader in diabetes care, to offer a new way for
people living with diabetes to access Lantus® (insulin glargine
injection) 100 Units/mL in the U.S. for only $35.
This collaboration builds on Sanofi’s recent announcement to
lower the list price for Lantus and cap out-of-pocket costs at $35
for all patients with commercial insurance, which goes into effect
January 1, 2024. It leverages GoodRx’s reach and scale to broaden
access and affordability for people living with diabetes and means
that, effective today, all Americans with a valid prescription,
regardless of insurance status, can use GoodRx at over 70,000 U.S.
retail pharmacies to access a 30-day supply of Lantus for only
$35.
The number of Americans living with diabetes is increasing every
year. Currently, an estimated 37.3 million Americans (approximately
11.3% of the U.S. population) have diabetes, and roughly 8.4
million of them use insulin, according to the American Diabetes
Association.
“Efforts to make insulin more accessible have been at the
forefront of the news for months, and a critical piece of
delivering on this promise is making it as simple as possible for
patients to get the lower price right at their regular pharmacy
counter. Sanofi is taking action and providing Americans who need
insulin with the ability to access Lantus in an easy and affordable
way, regardless of insurance status. We’re proud to collaborate
with them on this initiative,” said Dorothy Gemmell, Chief
Commercial Officer at GoodRx.
Patients can visit GoodRx.com/lantus to access the $35 price
coupon, which can be redeemed at any pharmacy that accepts GoodRx,
including CVS, Walgreens, and Walmart. This complements other
savings programs already offered by Sanofi, including offering
Lantus for $35 per month to people without insurance. GoodRx also
offers supportive resources to help consumers holistically manage
their condition, including discounts on continuous glucose monitors
and coupons for diabetes medications, as well as a Diabetes Hub
that offers diabetes-specific articles and resources written by
medical experts on GoodRx Health.
“Sanofi believes that no one should struggle to pay for their
insulin,” said Olivier Bogillot, Head of U.S. General Medicines at
Sanofi. “We are proud to collaborate with GoodRx to build on our
existing suite of industry-leading savings programs to expand
access and affordability pathways that can bring convenient and
meaningful impact at the pharmacy counter.”
Through its Pharma Manufacturer Solutions offering, GoodRx has
worked with 19 of the top 20 pharmaceutical manufacturers1 to
deliver savings options directly to relevant patients. By surfacing
important retail and specialty drug information, access solutions
such as copay cards and patient savings programs, and unique
programs where manufacturers can offer cash prices for their
medications, GoodRx can help pharmaceutical manufacturers increase
their reach to consumers who are looking for affordable ways to
access the treatments they need.
About GoodRx
GoodRx is a leading resource for healthcare savings and
information that makes healthcare affordable and convenient for all
Americans. We offer consumers free access to transparent and lower
prices for brand and generic medications, affordable and convenient
medical provider consultations via telehealth, and comprehensive
healthcare research and information. Since 2011, we have helped
consumers save over $60 billion and are one of the most downloaded
medical apps over the past decade.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
GoodRx Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding consumer savings and the benefits of our
offerings to consumers, GoodRx, Sanofi and other pharmaceutical
manufacturers. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to,
risks relating to our ability to achieve broad market education and
change consumer purchasing habits, changes in medication pricing
and pricing structures, our reliance on a limited number of
industry participants, the competitive nature of our industry,
risks related to government regulation of the internet, e-commerce,
consumer data and privacy, information technology and
cyber-security and the important factors discussed in the sections
entitled “Risk Factors” in GoodRx’s Annual Report on Form 10-K for
the year ended December 31, 2022, as updated by our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2023, and our
other filings with the Securities and Exchange Commission. These
factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management’s
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change.
1
Includes pharmaceutical manufacturers with
a commercialized portfolio consisting exclusively of (i) covid-19
vaccines and/or (ii) pharmaceuticals that are not dispensed at
retail or specialty pharmacies
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019208453/en/
Lauren Casparis press@goodrx.com
GoodRx (NASDAQ:GDRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
GoodRx (NASDAQ:GDRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024